Evidence map›Paper›PMID 36451642›Full record

ReviewCureus2022

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.

Andreea Parosanu, Ioana Miruna Stanciu, Cristina Pirlog, Cristina Orlov Slavu, Horia Cotan, Cristian Iaciu, Ana Maria Popa, Mihaela Olaru, Oana Moldoveanu, Baston Catalin and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andreea ParosanuOncology, Elias Emergency University Hospital, Bucharest, ROU.
Ioana Miruna StanciuMedical Oncology, Elias Emergency University Hospital, Bucharest, ROU.
Cristina PirlogOncology, Elias Emergency University Hospital, Bucharest, ROU.
Cristina Orlov SlavuOncology, Elias Emergency University Hospital, Bucharest, ROU.
Horia CotanOncology, Elias Emergency University Hospital, Bucharest, ROU.
Cristian IaciuOncology, Elias Emergency University Hospital, Bucharest, ROU.
Ana Maria PopaOncology, Elias Emergency University Hospital, Bucharest, ROU.
Mihaela OlaruOncology, Elias Emergency University Hospital, Bucharest, ROU.
Oana MoldoveanuUrology, Fundeni Clinical Institute, Bucharest, ROU.
Baston CatalinUrology, Fundeni Clinical Institute, Bucharest, ROU.
Cornelia NitipirOncology, Elias Emergency University Hospital, Bucharest, ROU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond to this newer therapy. As a result, it is crucial to identify predictive factors of response to immunotherapy in patients with kidney cancer. This review discusses the research investigating potential biomarkers of response to ICIs in renal cell carcinoma.

Indexed as

immune check-point inhibitorpredictive risk factorsrenal cell carcinoma (rcc)risk factor modelserum biomarkers

Identifiers

PMID36451642
PMCPMC9703028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.